These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12513901)

  • 41. Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study.
    Macalino GE; Mitty JA; Bazerman LB; Singh K; McKenzie M; Flanigan T
    Clin Infect Dis; 2004 Jun; 38 Suppl 5():S393-7. PubMed ID: 15156428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daily dosing of highly active antiretroviral therapy.
    Rosenbach KA; Allison R; Nadler JP
    Clin Infect Dis; 2002 Mar; 34(5):686-92. PubMed ID: 11823957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Viewpoint: adapting to new international tuberculosis treatment standards with medication monitors and DOT given selectively.
    Moulding TS
    Trop Med Int Health; 2007 Nov; 12(11):1302-8. PubMed ID: 17949402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiology of treatment failure: a focus on recent trends.
    Hull MW; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    Curr Opin HIV AIDS; 2009 Nov; 4(6):467-73. PubMed ID: 20048712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care.
    Abdool-Karim SS; Abdool-Karim Q; Friedland G; Lalloo U; El-Sadr WM;
    AIDS; 2004 Apr; 18(7):975-9. PubMed ID: 15096799
    [No Abstract]   [Full Text] [Related]  

  • 48. Modified directly observed therapy: sustained self-reported adherence and HIV health status.
    Mitty JA; Huang D; Loewenthal HG; MacLeod C; Thompson L; Bazerman LB
    AIDS Patient Care STDS; 2007 Dec; 21(12):897-9. PubMed ID: 18154486
    [No Abstract]   [Full Text] [Related]  

  • 49. Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead.
    Gaur AH; Belzer M; Britto P; Garvie PA; Hu C; Graham B; Neely M; McSherry G; Spector SA; Flynn PM;
    AIDS Res Hum Retroviruses; 2010 Sep; 26(9):947-53. PubMed ID: 20707731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving on success: what treating the urban poor in America can teach us about improving antiretroviral programmes in Africa.
    Amoroso A; Spencer DE; Redfield RR
    AIDS; 2004 Jun; 18 Suppl 3():S39-43. PubMed ID: 15322483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach.
    Smith-Rohrberg D; Altice FL
    Clin Infect Dis; 2006 Nov; 43(9):1221-2; author reply 1222-3. PubMed ID: 17029149
    [No Abstract]   [Full Text] [Related]  

  • 52. 'DOTS' and 'DOT' for delivering antiretroviral therapy in resource-poor countries.
    Harries AD
    AIDS; 2004 Mar; 18(5):830-1; author reply 831-2. PubMed ID: 15075526
    [No Abstract]   [Full Text] [Related]  

  • 53. Evidence-based health benefits management: strategies to optimize antiretroviral medication adherence and outcomes in HIV/AIDS.
    Zabinski RA
    J Manag Care Pharm; 2006 Sep; 12(7 Suppl B):S12-6. PubMed ID: 16984223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community.
    Di Paola A; Altice FL; Powell ML; Trestman RL; Springer SA
    Health Justice; 2014 Oct; 2(11):. PubMed ID: 25606368
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Matching social support to individual needs: a community-based intervention to improve HIV treatment adherence in a resource-poor setting.
    Muñoz M; Bayona J; Sanchez E; Arevalo J; Sebastian JL; Arteaga F; Guerra D; Zeladita J; Espiritu B; Wong M; Caldas A; Shin S
    AIDS Behav; 2011 Oct; 15(7):1454-64. PubMed ID: 20383572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of directly observed therapy (DOT) for tuberculosis: a review of multinational experience reported in 1990-2000.
    Hill AR; Manikal VM; Riska PF
    Medicine (Baltimore); 2002 May; 81(3):179-93. PubMed ID: 11997715
    [No Abstract]   [Full Text] [Related]  

  • 57. Feasibility of Four Interventions to Improve Treatment Adherence in Migrants Living with HIV in The Netherlands.
    Been SK; van de Vijver DAMC; Smit J; Bassant N; Pogány K; Stutterheim SE; Verbon A
    Diagnostics (Basel); 2020 Nov; 10(11):. PubMed ID: 33233835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Harnessing nanostructured systems for improved treatment and prevention of HIV disease.
    Monroe M; Flexner C; Cui H
    Bioeng Transl Med; 2018 May; 3(2):102-123. PubMed ID: 30065966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Directly observed therapy.
    Papineni P
    Lancet; 2022 Dec; 400(10369):2265-2266. PubMed ID: 36528380
    [No Abstract]   [Full Text] [Related]  

  • 60. Patient Compliance: Fact or Fiction?
    Mohiuddin AK
    Innov Pharm; 2019; 10(1):. PubMed ID: 34007538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.